Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02, FiscalAI reports. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.
Neumora Therapeutics Stock Down 9.5%
NMRA stock opened at $0.33 on Wednesday. The company has a 50-day moving average of $0.56 and a two-hundred day moving average of $1.68. Neumora Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50.
Insider Activity at Neumora Therapeutics
In other news, insider Daljit Singh Aurora sold 67,741 shares of Neumora Therapeutics stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $1.51, for a total value of $102,288.91. Following the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $73,612.50. The trade was a 58.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 176,060 shares of company stock valued at $269,390 in the last 90 days. Insiders own 26.94% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Neumora Therapeutics
Neumora Therapeutics Company Profile
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.
Featured Stories
- Five stocks we like better than Neumora Therapeutics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
